Bayer is spending billions on cell and gene therapies to drive its pharma business. These technologies are promising but unproven. It will take years to know whether the bets pay off. The new focus is critical, as analysts project pharma sales will drop over the next few years. The $58 billion German pharmaceutical giant Bayer…
